ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 560

Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome

Gwenny M. Verstappen1, Johan Bijzet1, Jolien F. van Nimwegen1, Martha S. van Ginkel1, Arjan Vissink2, Hendrika Bootsma1 and Frans G.M. Kroese1, 1Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Abatacept, B cells, biomarkers and rituximab, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Sjögren's Syndrome Poster I: Translational Research

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains are secreted into serum as free light chains (FLC). Compared to healthy individuals, elevated serum levels of polyclonal FLCs are seen in autoimmune diseases associated with increased B-cell activation, including primary Sjögren’s syndrome (pSS). In pSS, serum FLC levels correlate with IgG, rheumatoid factor and systemic disease activity.1 However, the clinical relevance of serum FLC levels as biomarker in pSS remains unclear. The objective of this study is to assess if I) FLCs are already elevated at the time of diagnosis, II) FLC levels can discriminate non-SS sicca from pSS patients, and III) FLCs can be used to monitor treatment response.

Methods:

Serum samples of 102 consecutive patients referred to our expertise center for suspicion of pSS were included. Patients were classified by a panel of 3 clinical experts as non-SS sicca, incomplete pSS or pSS and fulfillment of ACR-EULAR criteria for pSS was assessed. Longitudinal serum samples of pSS patients treated with rituximab (n=20) or abatacept (n=15) were also included. Kappa (κ) and lambda (λ) FLCs were measured in serum by the Freelite assay (Binding Site, UK). Area under the ROC curve (AUC) was used to assess the ability of serum FLC levels to predict a pSS diagnosis. Generalized estimating equations were used to measure changes during treatment.

Results:

At the time of diagnosis, FLCκ and FLCλ serum levels were significantly higher in pSS patients compared to non-SS sicca patients (FLCκ: median (IQR)=29 (17-39) vs. 15 (11-17) mg/L, p<0.001; FLCλ: 27 (18-34) vs. 15 (13-18) mg/L, p<0.001). The κ/λ ratio was slightly increased in pSS compared to non-SS sicca patients (p=0.045). FLCκ and FLCλ both showed good accuracy to discriminate pSS from non-SS (FLCκ: AUC=0.806, 95% CI=0.708-0.904; FLCλ: AUC=0.802, 95% CI=0.705-0.899). However, the accuracy of serum IgG was higher (AUC=0.885, 95% CI=0.811-0.959). Interestingly, FLCκ was also elevated (>20 mg/L) in 4/9 incomplete pSS patients. In two of them, also FLCλ was elevated (>32 mg/L). In patients fulfilling ACR-EULAR criteria, FLCκ and FLCλ levels correlated with systemic disease activity, assessed by EULAR Sjögren’s syndrome disease activity index (FLCκ: Spearman’s ρ=0.282, p=0.004; FLCλ: ρ=0.321, p=0.001). Treatment with rituximab significantly lowered FLCκ and FLCλ levels (p<0.001 for both). Treatment with abatacept also reduced FLCκ and FLCλ levels, although to a smaller extent (p=0.006 and p=0.087, respectively).

Conclusion:

Serum FLCs are elevated in pSS patients at the time of diagnosis and can discriminate non-SS sicca from pSS. FLCκ is already elevated in a large part of the incomplete SS patients and may serve as an early diagnostic biomarker. Furthermore, serum FLC levels can be used to monitor the effect of treatment on B-cell activity and may be more sensitive to change than serum IgG, because of a shorter half-life.

  1. Gottenberg et al., Ann Rheum Dis 2007;66:23-7.


Disclosure: G. M. Verstappen, None; J. Bijzet, None; J. F. van Nimwegen, None; M. S. van Ginkel, None; A. Vissink, None; H. Bootsma, None; F. G. M. Kroese, None.

To cite this abstract in AMA style:

Verstappen GM, Bijzet J, van Nimwegen JF, van Ginkel MS, Vissink A, Bootsma H, Kroese FGM. Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-relevance-of-serum-free-light-chain-level-as-biomarker-in-primary-sjogren%e2%80%b2s-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-relevance-of-serum-free-light-chain-level-as-biomarker-in-primary-sjogren%e2%80%b2s-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology